Galapagos NV
OTC:GLPGF

Watchlist Manager
Galapagos NV Logo
Galapagos NV
OTC:GLPGF
Watchlist
Price: 31.68 USD 1.25%
Market Cap: 2.1B USD

Operating Margin
Galapagos NV

-111.6%
Current
-51%
Average
-4.3%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-111.6%
=
Operating Profit
-320m
/
Revenue
286.8m

Operating Margin Across Competitors

No Stocks Found

Galapagos NV
Glance View

Market Cap
2.1B USD
Industry
Biotechnology

Founded in 1999, Galapagos NV emerged from the rich scientific collaboration between the Netherlands and Belgium, initially as a joint venture between the Dutch company Crucell and the Flemish biotech company Tibotec. In its early years, Galapagos carved a niche for itself by focusing on the discovery of novel targets leading to the development of human proteins for medicines. Through its proprietary technological platforms, Galapagos identifies and validates these targets, setting the stage for developing small molecules that inhibit these specific proteins. This unique approach positions the company at the forefront of innovative drug discovery, primarily targeting inflammatory diseases, fibrosis, and other conditions where there is a significant unmet medical need. Revenue for Galapagos is generated through several streams, most notably from strategic partnership deals and potential milestone payments in the biotech sector. The heart of its business model lies in deep collaborations with major pharmaceutical companies like Gilead Sciences, which bolster its financial stability and provide mutual benefits in drug development ventures. Additionally, Galapagos advances its proprietary drug candidates in clinical trials, aiming to bring them to market and secure approval from regulatory bodies. By successfully moving these candidates through clinical development phases, it stands to secure substantial future revenue from both commercialization and licensing deals. With its innovative science-focused strategy, Galapagos continues to propel forward, endeavoring to transform scientific insights into tangible therapeutic advancements.

GLPGF Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-111.6%
=
Operating Profit
-320m
/
Revenue
286.8m
What is the Operating Margin of Galapagos NV?

Based on Galapagos NV's most recent financial statements, the company has Operating Margin of -111.6%.

Back to Top